1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

12 Oct 2021
Admin
News Article

Syndax Pharmaceuticals Announces Closing Of Global Collaboration And License Agreement For Axatilimab

Syndax Pharmaceuticals, Inc. (Nasdaq: Sndx) Announced Today That The Hart-Scott-Rodino (Hsr) Antitrust Waiting Period Had Expired And That The Parties Closed The Exclusive Worldwide Collaboration And License Agreement Between Syndax And Incyte To Develop And Commercialize Axatilimab, Syndax'S Anti-Csf-1R Monoclonal Antibody. In Connection With Closing, Incyte Paid Syndax The $117 Million Upfront Initial License Fee, And Syndax Closed On Incyte'S $35 Million Equity Investment In The Company.Additional Information About The Collaboration Can Be Found In The Press Release Announcements Dated September 27, 2021, As Well As In Syndax'S Form 8-K Filed With The Securities And Exchange Commission (Sec) On September 27, 2021.About AxatilimabAxatilimab Is An Investigational Monoclonal Antibody That Targets Colony Stimulating Factor-1 Receptor, Or Csf-1R, A Cell Surface Protein Thought To Control The Survival And Function Of Monocytes And Macrophages. In Pre-Clinical Models, Inhibition Of Signaling Through The Csf-1 Receptor Has Been Shown To Reduce The Number Of Disease-Mediating Macrophages Along With Their Monocyte Precursors, Which Has Been Shown To Play A Key Role In The Fibrotic Disease Process Underlying Diseases, Such As Chronic Graft-Versus-Host Disease (Cgvhd) And Idiopathic Pulmonary Fibrosis (Ipf). Axatilimab Data Has Demonstrated Deep, Durable Responses And Multi-Organ Clinical Benefit In Patients With Cgvhd Refractory To Multiple Therapeutic Agents, And Is Currently Being Evaluated In The Global Pivotal Phase 2 Agave-201 Trial In Patients With Cgvhd. Axatilimab Was Granted Orphan Drug Designation By The U.S. Food And Drug Administration For The Treatment Of Patients With Cgvhd And Ipf. Axatilimab Is Being Developed Under An Exclusive Worldwide License From Ucb Entered Into Between Syndax And Ucb In 2016.About Syndax Pharmaceuticals, Inc.Syndax Pharmaceuticals Is A Clinical-Stage Biopharmaceutical Company Developing An Innovative Pipeline Of Cancer Therapies. The Company'S Pipeline Includes Sndx-5613, A Highly Selective Inhibitor Of The Menin

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!